Tessa Therapeutics is a clinical-stage cell therapy company focused on the development of autologous and off-the-shelf, allogeneic therapies targeting a wide range of cancers. Tessa’s Virus-Specific T cell (VST) platform harnesses the body’s potent anti-viral immune response and has shown early efficacy and a strong safety profile in the treatment of solid tumors. The Company has a proven track record of execution and an advanced clinical pipeline of autologous therapies – ongoing Ph III nasopharyngeal cancer trial, upcoming pivotal Ph II Hodgkin lymphoma trial – along with several earlier clinical-stage programs targeting cervical, head & neck, bladder, and lung cancer. In addition, Tessa is leveraging its VST platform to develop allogeneic therapies to address lymphomas and solid tumors. Key collaborators include Baylor College of Medicine, Parker Institute for Cancer Immunotherapy, St. Jude Children’s Research Hospital, and a joint venture in China with Guangzhou Knowledge City. The Company has advanced manufacturing and global logistics capabilities and is building a commercial manufacturing facility to be ready in 2020.
Immuno-Oncology, Immunotherapy, Oncology
8 Temasek Boulevard, #24-02
Suntec Tower Three